This article is a overview of trials in the United States. Adriamycin has definite antitumor activity in adult and childhood solid tumors and hematologic malignancies. Adriamycin probably lacks clinical cross resistance to standard antineoplastic agents, and may be more effective in patients with less advanced disease. The ultimate role of adriamycin therapy in the control of cancer will depend on the results of properly designed prospective clinical studies using adriamycin as a single agent, in combination chemotherapy, and in combined modality approaches.
|Number of pages||5|
|State||Published - 1975|